Shervin Assassi
YOU?
Author Swipe
View article: ALK5 inhibitor impact on bleomycin-induced systemic sclerosis mouse model via multifunctional optical coherence tomography
ALK5 inhibitor impact on bleomycin-induced systemic sclerosis mouse model via multifunctional optical coherence tomography Open
Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis, vascular dysfunction, and immune dysregulation, leading to significant morbidity and mortality. Noninvasive imaging techniques are critical for monitoring …
View article: Assessment of skin in patients with systemic sclerosis using high‐frequency ultrasound and shear wave elastography: A comparative study with histology, molecular and clinical parameters
Assessment of skin in patients with systemic sclerosis using high‐frequency ultrasound and shear wave elastography: A comparative study with histology, molecular and clinical parameters Open
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histological markers of skin fibrosis has not been repor…
View article: Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial Open
Background We investigated the prognostic potential of circulating biomarkers at baseline and the effects of nintedanib on changes in these biomarkers in subjects with progressive pulmonary fibrosis (PPF). Methods In the INBUILD trial, sub…
View article: Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease
Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease Open
Objective The common gain-of-function variant rs35705950, located in the promoter of MUC5B gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rh…
View article: Integrative exome sequencing and machine learning identify MICB and interferon pathway genes as contributors to SSc risk
Integrative exome sequencing and machine learning identify MICB and interferon pathway genes as contributors to SSc risk Open
View article: POS0947 ANTI-NOR-90 ANTIBODIES IN AN INTERNATIONAL COHORT OF 2140 SYSTEMIC SCLEROSIS SUBJECTS: CLINICAL ASSOCIATIONS
POS0947 ANTI-NOR-90 ANTIBODIES IN AN INTERNATIONAL COHORT OF 2140 SYSTEMIC SCLEROSIS SUBJECTS: CLINICAL ASSOCIATIONS Open
View article: POS0939 CLINICAL OUTCOME MEASURES THAT ARE READY FOR PHASE III TRIALS IN SYSTEMIC SCLEROSIS
POS0939 CLINICAL OUTCOME MEASURES THAT ARE READY FOR PHASE III TRIALS IN SYSTEMIC SCLEROSIS Open
View article: Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis
Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis Open
Objective We used data from the placebo arm of the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course…
View article: Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two <scp>US</scp> Cohorts
Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two <span>US</span> Cohorts Open
Objective Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we de…
View article: Psychometrics of inflammatory back pain criteria in the US population
Psychometrics of inflammatory back pain criteria in the US population Open
View article: Outcomes in Systemic Sclerosis–Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies
Outcomes in Systemic Sclerosis–Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies Open
Objective We aimed to compare the progression of systemic sclerosis–associated interstitial lung disease (SSc-ILD) based on serological status. Methods In a posthoc analysis of the SENSCIS trial (nintedanib vs placebo in SSc-ILD; ClinicalT…
View article: Assessment of skin fibrosis in a murine model of systemic sclerosis with multifunctional optical coherence tomography
Assessment of skin fibrosis in a murine model of systemic sclerosis with multifunctional optical coherence tomography Open
Our results indicate that OCT and its extensions effectively analyze dermal fibrosis. OCE revealed increased stiffness in fibrotic skin, OCTA showed vessel dilation, and OCT noted morphological changes in fibrosis tissue.
View article: Lack of association of the PLD4 SNP rs2841277 with systemic sclerosis in a European American population
Lack of association of the PLD4 SNP rs2841277 with systemic sclerosis in a European American population Open
This study aimed to examine whether a reported SSc-associated SNP rs2841277 in the PLD4 gene identified in an Asian population was also associated with SSc in European American (EA). The EA cohort consisting of 1005 SSc patients and 961 he…
View article: Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study
Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study Open
When the aim of the study is to identify a statistical model that best distinguishes between cohort groups using proteomics data and to uncover the biological pathways and disorders common among the selected proteins, the majority of widel…
View article: Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease Open
Objective: Safe, effective therapies are urgently needed for patients with systemic sclerosis. However, clinical trial recruitment is challenging given the limited number of people with systemic sclerosis and further restrictions imposed b…
View article: PIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation
PIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation Open
Systemic sclerosis (SSc), also known as scleroderma, is an autoimmune-driven connective tissue disorder that results in fibrosis of the skin and internal organs such as the lung. Fibroblasts are known as the main effector cells involved in…
View article: Unraveling the role of <scp>MiR</scp> ‐181 in skin fibrosis pathogenesis by targeting <scp>NUDT21</scp>
Unraveling the role of <span>MiR</span> ‐181 in skin fibrosis pathogenesis by targeting <span>NUDT21</span> Open
Systemic sclerosis (SSc) is a life‐threatening autoimmune disease characterized by widespread fibrosis in the skin and several internal organs. Nudix Hydrolase 21 (NUDT2 or CFIm25) downregulation in fibroblasts is known to play detrimental…
View article: A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale
A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale Open
The DAISY trial will evaluate the efficacy and safety of anifrolumab as a first-in-class treatment option for patients with both limited and diffuse cutaneous SSc and will provide insight into the contributions of type I interferon to SSc …
View article: Deletion of adipocyte Sine Oculis Homeobox Homolog 1 prevents lipolysis and attenuates skin fibrosis
Deletion of adipocyte Sine Oculis Homeobox Homolog 1 prevents lipolysis and attenuates skin fibrosis Open
Dermal fibrosis is a cardinal feature of systemic sclerosis (SSc) for which there are limited treatment strategies. This is in part due to our fragmented understanding of how dermal white adipose tissue (DWAT) contributes to skin fibrosis.…
View article: Single-cell transcriptomes and chromatin accessibility of endothelial cells unravel transcription factors associated with dysregulated angiogenesis in systemic sclerosis
Single-cell transcriptomes and chromatin accessibility of endothelial cells unravel transcription factors associated with dysregulated angiogenesis in systemic sclerosis Open
View article: Lack of Association of the PLD4 SNP rs2841277 With Systemic Sclerosis in a US Caucasian population
Lack of Association of the PLD4 SNP rs2841277 With Systemic Sclerosis in a US Caucasian population Open
Objective This study aimed to examine whether a reported SSc-associated SNP rs2841277 in the PLD4 gene identified in an Asian population was also associated with SSc in US Caucasians. Methods The US Caucasian cohort consisting of 1005 SSc …
View article: EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis
EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis Open
Objective Erythropoietin‐producing hepatocellular (Eph)/Ephrin cell–cell signaling is emerging as a key player in tissue fibrogenesis. The aim of this study was to test the hypothesis that the receptor tyrosine kinase EphB2 mediates dermal…
View article: Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures
Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures Open
Objective In the randomized Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to the normalization of systemic sclerosis (SSc) peripheral blood cel…
View article: A Prospective Observational Study of Disease Severity and Mortality in Hispanic American Patients With Systemic Sclerosis
A Prospective Observational Study of Disease Severity and Mortality in Hispanic American Patients With Systemic Sclerosis Open
Objective To characterize disease manifestations in Hispanic American patients with systemic sclerosis (SSc) in comparison with non‐Hispanic White and Black patients. Methods Longitudinal clinical characteristics were collected prospective…
View article: Sine Oculis Homeobox Homolog 1 Modulates Early Features of Systemic Sclerosis Skin Fibrosis
Sine Oculis Homeobox Homolog 1 Modulates Early Features of Systemic Sclerosis Skin Fibrosis Open
View article: Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features
Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features Open
View article: Reactome pathway analysis from whole-blood transcriptome reveals unique characteristics of systemic sclerosis patients at the preclinical stage
Reactome pathway analysis from whole-blood transcriptome reveals unique characteristics of systemic sclerosis patients at the preclinical stage Open
Objective This study aims to characterize differential expressed pathways (DEP) in subjects with preclinical systemic sclerosis (PreSSc) characterized uniquely by Raynaud phenomenon, specific autoantibodies, and/or capillaroscopy positive …
View article: Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) Open
Introduction Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF an…
View article: Methods for objective assessment of skin involvement in systemic sclerosis
Methods for objective assessment of skin involvement in systemic sclerosis Open
Purpose of review Skin fibrosis is the most prominent disease manifestation of systemic sclerosis (SSc). Although the treatment for other SSc manifestations has expanded over the years, there is limited progress in identifying effective tr…
View article: Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy Open
Objective Progressive pulmonary fibrosis (PPF) is the leading cause of death in systemic sclerosis (SSc). This study aimed to develop a clinical prediction nomogram using clinical and biological data to assess risk of PPF among patients re…